Skip to main content
TENAX THERAPEUTICS, INC. logo

TENAX THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TENX ISIN · US88032L2097 LEI · 549300J03O6B1IJ2B606 US Manufacturing
Filings indexed 939 across all filing types
Latest filing 2024-11-14 Major Shareholding Noti…
Country US United States of America
Listing US TENX

About TENAX THERAPEUTICS, INC.

http://www.tenaxthera.com/

Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and pulmonary diseases. The company's primary drug candidate is TNX-103, an oral formulation of levosimendan, for the treatment of heart failure. The intravenous form of levosimendan is already approved in numerous countries for acute decompensated heart failure, providing an established safety profile. Additionally, Tenax is developing a formulation of imatinib mesylate, a kinase inhibitor, for the treatment of pulmonary arterial hypertension (PAH). The company's development strategy is guided by clinical insights into cardiopulmonary disorders and is led by a management team with extensive experience in the field.

Recent filings

Filing Released Lang Actions
JANUS AMENDMENT
Major Shareholding Notification
2024-11-14 English
SC 13G/A
Major Shareholding Notification
2024-11-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-13 English
FORM 10-Q
Interim / Quarterly Report Q3 2024
2024-11-13 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2024, reporting the issuance of a press release announcing financial results for the third quarter ended September 30, 2024. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of the earnings information. The length is 3511 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights only, not the full quarterly report (IR).
2024-11-13 English
TENAX THERAPEUTICS, INC.
Major Shareholding Notification
2024-11-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.